Abt Nicholas B, Miller Lauren E, Parikh Anuraag, Bhattacharyya Neil
Department of Otolaryngology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, USA.
Ann Otol Rhinol Laryngol. 2022 Jul;131(7):775-781. doi: 10.1177/00034894211044231. Epub 2021 Sep 4.
To analyze insurance status effect on overall survival (OS) and disease-specific survival (DSS) in laryngeal cancer.
Cross-sectional population analysis.
Surveillance, Epidemiology, and End Results (SEER) database.
Laryngeal cancer patients from 2007 to 2016.
Kaplan-Meier method with log-rank statistic analyzed OS and DSS by insurance status. Multivariable cox proportional hazard modeling generated survival prognostic factors.
Of 19 667 laryngeal cancer cases, initial disease presentation was stage I: 7770 patients (39.5%), stage II: 3337 patients (17.0%), stage III: 3289 patients (16.7%), and stage IV: 5226 patients (26.6%). Patients had non-Medicaid insurance (15 523, 78.9%), had Medicaid (3306, 16.8%), or were uninsured (891, 4.5%). Mean and median OS for insured, Medicaid, and uninsured patients were 60.5, 49.6, and 56.6 and 74.0, 40.0, and 65.0 months, respectively. Following multivariable analysis, OS for insured, Medicaid, and uninsured patients was stage I: 87.9, 82.8, and 88.4 ( < .001), stage II: 79.1, 75.1, and 78.3 ( = .12), stage III: 68.7, 66.1, and 72.1 ( = .11), and stage IV: 57.1, 51.7, and 50.3 ( < .001) months. DSS mean survival times were 77.0, 65.8, and 67.7 months ( < .001) for insured, Medicaid, and uninsured patients. Age (HR: 1.02/year, < .001) and black (HR: 1.15, = .001) compared to white race predicted worse survival. Compared to insured status, Medicaid insurance carried a death hazard ratio of 1.40 ( < .001) and uninsured status had a death hazard ratio of 1.40 ( < .001).
Insured laryngeal cancer patients had prolonged OS and DSS compared to Medicaid and uninsured patients. Medicaid patients had equivalent survival outcomes to uninsured patients.
2c.
分析保险状况对喉癌患者总生存期(OS)和疾病特异性生存期(DSS)的影响。
横断面人群分析。
监测、流行病学和最终结果(SEER)数据库。
2007年至2016年的喉癌患者。
采用Kaplan-Meier法和对数秩统计量,按保险状况分析OS和DSS。多变量Cox比例风险模型生成生存预后因素。
在19667例喉癌病例中,初始疾病分期为I期:7770例患者(39.5%),II期:3337例患者(17.0%),III期:3289例患者(16.7%),IV期:5226例患者(26.6%)。患者拥有非医疗补助保险(15523例,78.9%)、医疗补助保险(3306例,16.8%)或未参保(891例,4.5%)。参保、医疗补助和未参保患者的OS均值和中位数分别为60.5、49.6和56.6个月以及74.0、40.0和65.0个月。多变量分析后,参保、医疗补助和未参保患者的OS在I期分别为87.9、82.8和88.4(P<0.001),II期分别为79.1、75.1和78.3(P = 0.12),III期分别为68.7、66.1和72.1(P = 0.11),IV期分别为57.1、51.7和50.3(P<0.001)个月。参保、医疗补助和未参保患者的DSS平均生存时间分别为77.0、65.8和67.7个月(P<0.001)。与白人相比,年龄(风险比:每年1.02,P<0.001)和黑人(风险比:1.15,P = 0.001)预示生存情况较差。与参保状况相比,医疗补助保险的死亡风险比为1.40(P<0.001),未参保状况的死亡风险比为1.40(P<0.001)。
与医疗补助和未参保患者相比,参保喉癌患者的OS和DSS延长。医疗补助患者与未参保患者的生存结果相当。
2c。